Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter, Prospective Study

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

September 30, 2027

Conditions
Crohn Disease (CD)VedolizumabIntestinal UltrasoundPredictor
Trial Locations (1)

410000

RECRUITING

The Third Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
collaborator

The First Affiliated Hospital of University of South China

OTHER

collaborator

The First People's Hospital of Changde City

OTHER

collaborator

The Central Hospital of Shaoyang City

UNKNOWN

collaborator

First People's Hospital of Chenzhou

OTHER

lead

The Third Xiangya Hospital of Central South University

OTHER

NCT07093294 - Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter, Prospective Study | Biotech Hunter | Biotech Hunter